Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nal-anti TIGIT
- Development stage
- Preclinical
- Lead developer
- TuHURA Biosciences
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nal-anti TIGIT is a bifunctional antibody-drug conjugate (ADC) developed by TuHURA Biosciences for the treatment of myelodysplastic syndromes (MDS). This prototype ADC combines a small molecule Delta receptor inhibitor with an anti-TIGIT antibody. The drug is designed to target myeloid-derived suppressor cells (MDSCs), which are known to suppress T and NK cell function and contribute to immune evasion in the tumor microenvironment. By inhibiting the Delta receptor on MDSCs and blocking the TIGIT checkpoint pathway, nal-anti TIGIT aims to modulate immunosuppression, overcome resistance to checkpoint inhibitors, and enhance antitumor immunity. Its primary indication is high-risk myelodysplastic syndromes[1][2].
- Other names
- Nal-TIGITNal Anti TIGIT
02
Targets
DOR (Opioid Receptor Delta 1)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on Nal-anti TIGIT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nal-anti TIGIT.